


IN THE CLAIMS

21. (Currently Amended) Monocyclic compounds of formula (I)

wherein:



- 15 X_1, X_2, X_3, X_4 are the same or different, and are selected from the group consisting of $-\text{CONR}-$, $-\text{NRCO}-$, $-\text{CH}_2\text{NR}-$, and $-\text{NRCH}_2-$ where R is selected from the group consisting of H, C_{1-3} alkyl, and benzyl;
- f and m are the same or different, and is are a number selected from the group consisting of 0, 1 and 2;
- 20 R_1 and R_2 , are the same or different, and represent:
- $-(\text{CH}_2)_r \text{Ar}$ where r is 0, 1 or 2 and Ar is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, optionally substituted with up to 2 substituents selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkyloxy, C_{2-4} amino-alkyloxy,
- 25 halogens, OH, NH_2 , CN, and NR_6R_7 , where R_6 and R_7 , same or different, are H or C_{1-3} alkyl,
- R_3 is $-(\text{CH}_2)_r \text{Ar}_1$ where r is 0, 1 or 2 and Ar_1 is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, and benzimidazole,

- optionally substituted with up to 2 groups selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkyloxy, amino-alkyloxy, halogens, OH, NH₂, and NR₆R₇, where R₆ and R₇, same or different, are H or C₁₋₃ alkyl,
- R₄ is ~~NR₈R₉~~; -N(R₁₁)CO(CH₂)_hR₁₂; or -COR₁₃; where R₅ is H; where R₈ is H or C₁₋₃ alkyl; h is 0, 1, 2 or 3; and R₉ is selected from the group consisting of methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl optionally mono or di-substituted by oxygen on the S atom, piperidyl, optionally substituted on the N-atom by a C₁₋₃ alkyl, C₁₋₃ acyl, aminosulfonyl, or methanesulfonyl; or a group-(CH₂)_gR₁₀ where g is 1, 2, or 3 and R₁₀ is selected from the group consisting of morpholine, furan and CN;
- or R₈ and R₉ together with the N atom to which they are linked form a piperazine optionally substituted at the other N atom ~~substituted~~ by a C₁₋₃ alkyl, C₁₋₃ acyl or methanesulfonyl;
- N(R₁₁)CO(CH₂)_hR₁₂ where R₁₁ is H or C₁₋₃ alkyl; h is 0, 1, 2 or 3; and R₁₂ is selected from the group consisting of morpholine, pyrrolidine optionally substituted with a hydroxy or hydroxymethyl, piperidine optionally substituted with a 4-hydroxy/ or 4-carboxyamido ~~or 4-aminosulfonyl group~~;
- piperazine optionally substituted on the N-atom by 4-aminosulfonyl, C₁₋₃ alkyl, triazole, tetrazole, 5-mercapto-tetrazole, furan, thiophene, thiomorpholine, optionally mono or di-oxygenated on the S-atom, and ~~amino-cyclohexane~~ cyclohexan-1-yl-amino optionally substituted by a hydroxy group;
- COR₁₃ wherein R₁₃ is a member selected from the group consisting of morpholine and piperazine optionally substituted by a C₂₋₆ alkyl containing one or more hydroxy groups;
- their enantiomers and mixtures thereof, their diastereoisomers, and their pharmaceutically acceptable salts.

22. (Currently Amended)

Compound according to Claim 21 wherein:

f is 1

m is 0

X₁, X₂, X₃, X₄, are the same or different and are a member selected from the group consisting of -CONR- and -NRCO-,

5 where R is H or methyl,

R₁ and R₂ are the same or different, are:

-CH₂Ar wherein Ar is an aromatic group selected from the group consisting of benzene, pyridine, indole, optionally substituted with up to two substituents selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkyloxy, C₂₋₄ amino alkyloxy, halogens, OH, NH₂, CN, and NR₆R₇,
10 where R₆ and R₇, same or different, and are H or C₁₋₃ alkyl;

R₃ is -CH₂Ar₁ wherein Ar₁ is an aromatic group selected from the group consisting of alpha naphthyl, beta naphthyl, phenyl, phenyl substituted with up to two substituents selected from the group consisting of C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkyloxy, halogens, OH, and NH₂.

23. (Currently Amended) Compounds according to Claim 22 wherein:

15 - X₁, X₂, X₃, X₄ are -CONH-,

- R₁ is indol-3-yl-methyl

- R₂ is phenyl-methyl optionally substituted with up to two substituents selected from the group consisting of chlorine, fluorine, CF₃, OH and CN; or ~~are~~ is selected from the group consisting of 3-pyridyl-methyl and 4-pyridyl-methyl;

20 - R₃ is benzyl.

24. (Previously Added) Compounds according to claim 23 wherein:

R₄ is a group NR₈R₉ wherein:

25 R₈ is H or methyl;

R₉ selected from the group consisting of 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyran-4-yl, 1,1-dioxo-tetrahydrothiopyran-4-yl, N-methyl-4-piperidinyl, N-methanesulfonyl-4-piperidinyl, and N-aminosulfonyl-4-piperidinyl,

or R₈ and R₉ together with the N atom to which they are linked represent N-methyl-piperazinyl,

5 N-acetyl-piperazinyl or N-methanesulfonyl-piperazinyl.

25. (Previously Amended) Compounds according to Claim 24 represented by:

- i) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- 10 ii) cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- iii) cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- iv) cyclo{Suc[1-(R)-(4-tetrahydrothiopyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- v) cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- 15 vi) cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- vii) cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- viii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- 20 ix) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- x) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- xi) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}
- 25 xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF₃)-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

-CH₂NH}}

xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH₂-C₆H₅)

-CH₂NH}}

xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH₂-C₆H₅)

5 -CH₂NH}}

xv) cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)

-CH₂NH}}

xvi) cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)

-CH₂NH}}

10 xvii) cyclo{Suc[1-(R)-4-methyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xviii) cyclo{Suc[1-(R)-4-acetyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]} or

xix) cyclo{Suc[1-(R)-4-methylsulfonyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}.

15

26. (Previously Amended) Compounds according to Claim 23 wherein:

R₄ represents a group NR₈R₉, where R₈ is H and R₉ is methanesulfonyl, tosyl or a group

-(CH₂)_gR₁₀, wherein g is 1 or 2 and R₁₀ is morpholine, furan, or CN.

20

27. (Previously Amended) Compounds according to claim 26 represented by:

xx) cyclo{Suc[1-(S)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxi) cyclo{Suc[1-(R)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxii) cyclo{Suc[1-(S)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxiii) cyclo{Suc[1-(R)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

25

xxiv) cyclo{Suc[1-(S)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxv) cyclo{Suc[1-(R)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxvi) cyclo{Suc[1-(R)-(2-furyl)methylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]} or

xxvii) cyclo{Suc[1-(R)-cianomethylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}.

5

28. (Previously Added) Compounds according to claim 23 wherein:

R₄ is a group - N(R₁₁)CO(CH₂)_h-R₁₂ wherein R₁₁ is H, h is 0 or 1, and R₁₂ is selected from the group consisting of 1-tetrazolyl, 5-mercapto-tetrazol-1-yl, 1-triazolyl, furanyl, thiophenyl, morpholine, 4-
10 hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-pyrrolidine, 2-hydroxymethylpyrrolidine, 4-methyl-piperazine, 4-aminosulfonyl-piperazine, 1-oxo-thiomorpholine, and 4-hydroxy-cyclohexan-1-yl-amino.

29. (Previously Added) Compounds according to Claim 28 represented by:

15 xxviii) cyclo{Suc[1-(R)-2-(4-morpholino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxix) cyclo{Suc[1-(S)-2-(4-morpholino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxx) cyclo{Suc[1-(S)-2-(tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxxii) cyclo{Suc[1-(R)-2-(tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

20 xxxii) cyclo{Suc[1-(S)-2-(5-mercapto-tetrazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxxiii) cyclo{Suc[1-(R)-2-([1,2,4]triazol-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxxiv) cyclo{Suc[1-(R)-2-(furanyl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

25 xxxv) cyclo{Suc[1-(R)-2-(thiophen-3-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxxvi) cyclo{Suc[1-(R)-(4-morpholino)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

xxxvii) cyclo{Suc[1-(R)-2-(4-hydroxy-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}

- C₆H₅)-CH₂NH]}}
- xxxviii) cyclo{Suc[1-(R)-2-(4-aminocarbonyl-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}
- xxxix) cyclo{Suc[1-(R)-2-(3-hydroxy-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}
- 5 -C₆H₅)-CH₂NH]}}
- xl) cyclo{Suc[1-(R)-2-(2-(S)-hydroxymethyl-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}
- xli) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}
- 10 xlii) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}
- xliii) cyclo{Suc[1-(R)-2-(4-aminosulfonyl-piperazin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}
- xliv) cyclo{Suc[1-(R)-2-(1-oxo-thiomorpholin-4-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}
- 15 CH₂NH]}} or
- xlv) cyclo{Suc[1-(R)-2-(*trans*-4-hydroxy-cyclohexan-1-yl-amino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}.
- 20 30. (Previously Amended) Compounds according to Claim 23 wherein:
- R₄ represents a group COR₁₃ wherein R₁₃ is morpholine.
31. (Previously Amended) Compounds according to claim 30 represented by:
- xlvi) cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH₂-C₆H₅)-CH₂NH]}}.
- 25

32. (Previously Added) Pharmaceutical compositions containing as active principle compounds of general formula (I) according to Claim 21 in combination with pharmaceutically acceptable carriers or excipients.

33. (Previously Added) A method for the treatment of the bronchospastic component of
5 asthma, cough, pulmonary irritation, intestinal spasms or local spasms of bladder, ureters during cystitis, kidney infections and colics wherein amounts of 0.1 to 10mg/kg body weight of an active principle represented by compounds of formula (I) according to Claim 21 are administered to the patient.